Gluten Intolerance Treatment Market Snapshot (2023 to 2033)
The global gluten intolerance treatment market reached a valuation of US$ 536.85 million in the year 2022. With a robust CAGR of 13.2% from 2023 to 2033, this market is expected to reach US$ 661.4 million by 2023 and US$ 5,328.09 million by 2033.
Several individuals experience gluten sensitivity, which is also known as Celiac disease. It is an autoimmune condition in which eating gluten-containing foods causes damage to the small intestine's lining. Such a digestive problem makes it challenging for the body to absorb nutrients including iron, calcium, folate, and fat. This genetic ailment is prevalent in persons with autoimmune thyroid disease, type 1 diabetes, Down syndrome, Addison's disease, microscopic colitis, and rheumatoid arthritis.
Growing diabetes cases, favorable government policies in the Western countries, an increase in the number of medical studies for drugs to treat gluten intolerance disease, and an increase in the intake of foods like beer, bread, soda, and pizza that really are high in protein and therefore increase the consumption of gluten, which causes gluten intolerance, are all important factors driving the market growth. Also, in the anticipated period of 2023 to 2033, growing technical developments, expanding modernization in the healthcare industry, and expanding activities in research and development will further generate new chances for the gluten intolerance treatment market.
In the next few years, there will be a substantial increase in the market for the treatment of gluten intolerance, driven by:
Several therapeutic vaccinations and anti-inflammatory medications in development that are intended to replace or complement a gluten-free diet
Increasing healthcare costs,
Expansion of medical research,
Increased knowledge about the condition
Extensive research and development are still going on in the domain of the treatment of gluten intolerance. The landscape of medicinal therapy for gluten intolerance has changed over the past ten years, going from being only an idea to having more than a dozen potential drugs in patient studies. Several of the potential options function by limiting the effects of unintentional gluten consumption.
For instance, latiglutenase is consumed with meals and includes enzymes that dissolve gluten inside the stomach so that people with gluten intolerance disease can safely consume the protein. Contrarily, larazotide acts by shielding the interior of the small intestine from gluten-containing substances that go through the digestive system. Last but not least, a medicine code-named PRG-015 is designed to lessen the body's inflammatory reaction to minute levels of gluten. Clinical studies are still being conducted at Columbia to examine all three of these substances.
Another example is that of ActoBio Therapeutics™ which received FDA approval for an Investigational New Drug (IND) application for the novel orally-delivered pharmaceutical candidate AG017, for the treatment of gluten intolerance treatment. With the development of antigen-specific immunological tolerance that can stop, slow down, or reverse the illness, ActoBiotics® programs are ideally adapted to meet unmet requirements in a variety of autoimmune as well as allergic disorders. The second experimental immunotherapy option for an antigen-specific antigen will be ActoBiotics® AG017 for the therapy of gluten intolerance.
Based on the secure food-grade bacteria Lactococcus lactis that has been precisely engineered to produce a gliadin peptide in conjunction with an immunomodulating cytokine, ActoBio TherapeuticsTM is producing oral ActoBiotics® AG017 capsules. The experimental immunotherapy candidate ActoBiotics® AG017 may be able to treat antigen-specific gluten intolerance. Such developments are expected to boost the demand for the treatment of gluten intolerance diseases and hence open up new avenues for various firms.
Globally, due to their great incidence and developed healthcare systems, North America and Europe are the two biggest marketplaces for gluten intolerance treatment. On the other hand, considering that the Saharawi African population has the greatest frequency of illness, Africa is a market with significant potential.
Data Point
Key Statistics
Expected Market value in 2023
US$ 661.4 million
Expected Market value in 2033
US$ 5,328.09 million
Growth Rate (2023 to 2033)
13.2% CAGR from 2023 to 2033
Gluten intolerance is global health concern that causes autoimmune disease such as celiac disease, dermatitis Herpetiformis and gluten ataxia etc. moreover, the prevalence rate of celiac disease was 0.4% in South America, 0.5% in Africa and North America, 0.6% in Asia, and 0.8% in Europe and Oceania.
Rise in number of celiac disease patients is expected to fuel the market growth in the forecasting period. More than 80% of this population is not aware that they are suffering from celiac disease. The emerging demand for gluten intolerance treatment is largely arising from the growing development activities in the clinical trials.
The major factor driving the growth of gluten intolerance treatment market is an increase in the development of diagnostic methods coupled with growing awareness regarding the gluten related autoimmune disorders.
There are limited treatment option are available for gluten intolerance disease. Key players operating in diseases treatment market can find this as lucrative opportunity to invest in bring new treatment for effective drugs of gluten intolerance.
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
Gluten Intolerance Treatment Market: Drivers and Restraints
Till now there is few treatment option available for gluten intolerance. There is growth in the availability of gluten in food products leads to the rise in number of celiac disease patients. An increasing in number of gluten intolerance patient population is anticipated drive the gluten intolerance treatment market.
Moreover, growth in demand from millennial, improvement in marketing activities, and improved distribution channels drive the market growth. The impact of these drivers is expected to increase significantly due to increase in investments by drug manufacturing companies.
However, drug cost is a factor projected to restrain the gluten treatment market growth. Additionally, for gluten intolerance patient prefer gluten free diet option than drug treatment also hamper the gluten intolerance treatment market. With increase in drug research focused towards gluten intolerance, it will generate new avenues and opportunities for key players to have lucrative share in gluten intolerance treatment market with new drug launch.
Beside, with favorable reimbursement policies and health services in developed economies such as North America and Europe will also propel the growth of gluten intolerance treatment in the forecasting period.
Gluten Intolerance Treatment Market: Overview
The growth of gluten intolerance treatment market will increase due to increase in disease burden of gluten intolerance. Based on drug type, gluten intolerance treatment market has been segmented into Antihistamines and Epinephrine.
Based on indication, gluten intolerance treatment market has been segmented into celiac disease, dermatitis Herpetiformis, depression and gluten ataxia. Based on Distribution channel, Gluten Intolerance Treatment market has been segmented into hospital pharmacy, retail pharmacy, online pharmacy and specialty pharmacy.
Based on geography, the global gluten intolerance treatment market is segmented into seven key regions viz. North America, Europe, Latin America, East Asia, Oceania, South Asia, and Middle East & Africa. North America is expected to show significant growth for global Gluten Intolerance treatment market due to rising prevalence of Celiac Disease and availability of well-developed R&D facilities.
Likewise, Europe is also projected to be second largest market for gluten intolerance treatment due to increasing prevalence of the disease in the region. Besides, enhanced drug development and increased R&D expenditure on diseases treatment is also going to fuel the market growth. In terms of highest market growth, Asia-Pacific is expected to lead the gluten intolerance treatment market.
Moreover, Latin America region will show the significant demand for the gluten intolerance treatment, due to the regional government initiative towards research and development in countries like Brazil and Mexico.
Gluten intolerance treatment Market: Key players
Some of the key players present in global Gluten intolerance treatment market is
ActoBio Therapeutics
Calypso Biotech
Alvine Pharmaceuticals
ImmusanT
Artielle
Funzyme Biotechnologies
Innovate Biopharma
AMYRA Biotech AG
Vactech
Alba Therapeutics Corp
PVP Biologics and others.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need and save 40%!
The report covers exhaust analysis on Gluten intolerance treatment Market
Market Segments
Market Dynamics
Market Size
Supply & Demand
Current Trends/Issues/Challenges
Competition & Companies involved
Technology
Value Chain
Report on Gluten intolerance treatment Market includes regional analysis
North America (USA, Canada)
Latin America (Mexico. Brazil)
Europe (Germany, Italy, France, United Kingdom, Spain, , Russia)
East Asia (China, Japan, South Korea)
South Asia (India, ASEAN)
Oceania (Australia, New Zealand)
Middle East and Africa (GCC Countries, South Africa, Northern Africa)
The report on gluten intolerance treatment Market is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, inputs from industry experts and industry participants across the value chain.
The report provides in-depth analysis of parent market trends, macro-economic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies.
